DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, has announced its participation in several prominent investor conferences in May 2025. This move aligns with their mission to advance innovative treatments for severe ischemic diseases, particularly targeting preeclampsia and acute ischemic stroke.

The inaugural event will be the RBC Capital Markets Global Healthcare Conference, taking place from May 20 to May 21, 2025, in New York City, where DiaMedica's management will conduct one-on-one meetings with investors. Concurrently, the company will also be featured at the H.C. Wainwright 3rd Annual BioConnect Conference on May 20, during which management is set to engage in a fireside chat at 3:30 PM ET. This session will be accessible via a live webcast, and a replay will subsequently be available on the company’s website.

Following these events, DiaMedica will attend the 22nd Annual Craig-Hallum Institutional Investor Conference on May 28, 2025, in Minneapolis, Minnesota, offering additional one-on-one meeting opportunities.

DiaMedica's flagship product, DM199, represents the first recombinant form of the KLK1 protein, which has been recognized in Asia for its therapeutic use in treating acute ischemic stroke, preeclampsia, and other vascular conditions. The company remains committed to addressing significant unmet medical needs and improving patient outcomes.

Investors and stakeholders interested in more information about DiaMedica's upcoming activities and product developments can visit their official website at www.diamedica.com, or engage with designated investor relations representatives. This proactive approach to investor engagement underscores DiaMedica's commitment to transparency and collaboration in the healthcare investment community.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is positioning itself for potential growth by participating in key investor conferences in May 2025. As a clinical-stage biopharmaceutical company focused on severe ischemic diseases, DiaMedica’s forthcoming presence at events such as the RBC Capital Markets Global Healthcare Conference and the H.C. Wainwright 3rd Annual BioConnect Conference is expected to attract significant investor attention.

Management’s engagement in one-on-one meetings and a fireside chat at the BioConnect Conference provides an excellent opportunity for potential investors to gain insights into the company’s vision, pipeline, and strategic direction. Specifically, DiaMedica's lead candidate, DM199, holds promise due to its role as the first pharmaceutically active form of the KLK1 protein, with applications in treating acute ischemic stroke and preeclampsia, conditions that have considerable unmet medical needs.

Investors should monitor these conferences closely. Positive updates or data presented about DM199's efficacy and advancements in its development could lead to increased interest and momentum in DMAC shares. Moreover, the ability to connect directly with management allows investors to gauge the company’s commitment and clarity regarding its future.

With the biopharma sector often driven by breakthroughs and updates on clinical trials, any favorable news during these engagements could substantially enhance market sentiment around DiaMedica. That being said, potential investors should remain cautious and perform thorough due diligence, considering the inherent risks associated with early-stage biopharmaceutical firms.

In conclusion, DiaMedica Therapeutics' participation in these May conferences is a strategic move that could bolster investor interest and potentially lead to a favorable uptick in share performance. Investors should prepare for any pertinent developments during these events as they might provide valuable insights into DMAC's future trajectory.